Price target
12.400.00 0.00%
The 11 analysts offering 1 year price forecasts for BO1 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 12 analysts giving stock ratings to BO1 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
BO1 EPS for the last quarter is −0.26 CHF despite the estimation of −0.21 CHF. In the next quarter EPS is expected to reach −0.19 CHF. Track more of BIOCRYST PHARMACTL financials and stay on top of what is up with the company.
In the next quarter BIOCRYST PHARMACTL revenue is expected to reach 77.24 M CHF. Check out BIOCRYST PHARMACTL revenue and earnings and make informed decisions.
According to analysts, BO1 price target is 12.40 CHF with a max estimate of 26.93 CHF and a min estimate of 5.39 CHF. Check if this forecast comes true in a year, meanwhile keep track of the current situation with BO1 news and stock market news.
We've gathered opinions of 12 analysts rating BO1 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.